Press release: Sanofi successfully prices USD 3 billion of bond issue

Core Viewpoint - Sanofi has successfully priced a $3 billion offering of notes across five tranches, intending to use the net proceeds for general corporate purposes [1] Group 1: Offering Details - The offering consists of $400 million fixed rate notes due November 2027 at an interest rate of 3.75% [6] - It includes $500 million floating rate notes due November 2027, bearing interest at compounded SOFR plus 0.46% [6] - Additionally, there are $400 million fixed rate notes due November 2028 at an interest rate of 3.80% [6] - The offering also features $500 million floating rate notes due November 2028, with interest at compounded SOFR plus 0.54% [6] - Lastly, $1,200 million fixed rate notes due November 2032 are included, bearing an interest rate of 4.20% [6] Group 2: Underwriters - Barclays Capital Inc., BNP Paribas Securities Corp., and BofA Securities, Inc. acted as Global Coordinators for the offering [2] - The Joint Book-Running Managers include Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, MUFG Securities Americas Inc., and Natixis Securities Americas LLC [2] Group 3: Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives and delivering growth through innovative medicines and vaccines [3] - The company aims to address urgent healthcare, environmental, and societal challenges, guided by a commitment to scientific progress [3] - Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY, indicating its presence in major financial markets [4]